ORIC PHARMACEUTICALS INC

ORIC Pharmaceuticals is a clinical-stage biopharmaceutical company focused on developing novel therapies to overcome resistance mechanisms in cancer. Its pipeline includes small molecule inhibitors targeting specific pathways involved in tumor growth and survival. The company's research is centered on addressing unmet needs in oncology, with programs in early and later-stage clinical trials. As a clinical-stage entity, ORIC does not yet have approved products for commercial sale.

ORIC Pharmaceuticals' common stock is listed on the Nasdaq Global Select Market under the ticker symbol ORIC. This exchange is a major U.S. marketplace for growth-oriented and biotechnology companies. Investors can trade ORIC shares through brokerage accounts that provide access to Nasdaq-listed securities. The listing venue ensures liquidity and regulatory oversight typical of U.S. exchanges.

For the most recent performance of ORIC stock, including price changes over various periods, please refer to the live data and charts provided on this page. Stock performance can fluctuate based on clinical trial updates, financial reports, and broader market conditions. The displayed metrics offer the latest available information to assess recent trends.

The 52-week range for ORIC stock, which shows the lowest and highest prices over the past year, is available in the key statistics section on this page. This range helps investors understand the stock's volatility and price boundaries over a trailing 12-month period. For current figures, please check the latest data displayed.

Evaluating ORIC's valuation requires considering its clinical-stage status, as traditional metrics like P/E ratios may not apply without earnings. Investors often look at cash reserves, pipeline potential, and comparisons to peers in the biotechnology sector. Analyst estimates and discounted cash flow models, while speculative, can provide context. The valuation metrics displayed on this page offer a starting point for analysis.

Key risks for ORIC include the high uncertainty of clinical trial outcomes, potential regulatory delays, and the need for substantial capital to fund research and development. As a clinical-stage company, it faces competition, intellectual property challenges, and the possibility of adverse safety or efficacy results. Market sentiment toward biotechnology stocks and broader economic conditions can also impact the share price.